ArticlebioRxiv : the preprint server for biology2021
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.
Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis.BMC infectious diseases · 2022Pooled it
- The Emerging Role of Olfactory Receptors: From Genomics to Precision Medicine.Molecular diagnosis & therapy · 2026Review
- Soil Metaproteomics for Microbial Community Profiling: Methodologies and Challenges.Current microbiology · 2024Review
- N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.Human genetics · 2024Article
- DNA methylation: an emerging paradigm of gene regulation under drought stress in plants.Molecular biology reports · 2024Review
- Serine metabolism in macrophage polarization.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- An expanded RT-PCR melting temperature coding assay to rapidly identify all known SARS-CoV-2 variants and sub-variants of concern.Scientific reports · 2023Article
- Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.Breast cancer research : BCR · 2023Article
- Comparing the signaling and transcriptome profiling landscapes of human iPSC-derived and primary rat neonatal cardiomyocytes.Scientific reports · 2023Article
- Soil viral diversity, ecology and climate change.Nature reviews. Microbiology · 2023Review
- Innate immune evasion strategies of SARS-CoV-2.Nature reviews. Microbiology · 2023Review
- Forces of Change: Optical Tweezers in Membrane Remodeling Studies.The Journal of membrane biology · 2022Review
- Paraquat is an agonist of STIM1 and increases intracellular calcium levels.Communications biology · 2022Article
- Oct4 dependent chromatin activation is required for chicken primordial germ cell migration.Stem cell reviews and reports · 2022Article
- Single-cell atlases: shared and tissue-specific cell types across human organs.Nature reviews. Genetics · 2022Review
- A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus.Applied microbiology and biotechnology · 2022Article
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants.Scientific reports · 2022Article
- Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2.Tropical medicine and health · 2022Article
- How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?Bulletin of the National Research Centre · 2022Review
Corrections and comments
- Updated by
Authors and funding
24 authors at 3 institutions in 1 country.
Funding
Abstract
COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million deaths to date. Although multiple vaccines are available, breakthrough infections occur especially by emerging variants. Effective therapeutic options such as monoclonal antibodies (mAbs) are still critical. Here, we report the development, cryo-EM structures, and functional analyses of mAbs that potently neutralize SARS-CoV-2 variants of concern. By high-throughput single cell sequencing of B cells from spike receptor binding domain (RBD) immunized animals, we identified two highly potent SARS-CoV-2 neutralizing mAb clones that have single-digit nanomolar affinity and low-picomolar avidity, and generated a bispecific antibody. Lead antibodies showed strong inhibitory activity against historical SARS-CoV-2 and several emerging variants of concern. We solved several cryo-EM structures at ∼3 Å resolution of these neutralizing antibodies in complex with prefusion spike trimer ectodomain, and revealed distinct epitopes, binding patterns, and conformations. The lead clones also showed potent efficacy
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.